Zevra Therapeutics (ZVRA) closed at $9.40 on November 17, 2026, up 1.6% from the previous close, on volume of 765,861 shares (30-day average 928,258).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 12, 2026 | Calendar Put Spread | 17-Dec-27 : 21-Jan-28 10 P | 9,070 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Canaccord Genuity Reaffirms Their Buy Rating on Zevra Therapeutics (ZVRA)
TipRanks (Mon, 16-Nov 7:15 AM ET)
TipRanks (Mon, 16-Nov 6:16 AM ET)
Zevra Therapeutics Earnings Call Highlights MIPLYFFA Momentum
TipRanks (Sat, 14-Nov 8:10 PM ET)
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Zevra Therapeutics (ZVRA)
TipRanks (Fri, 13-Nov 4:30 PM ET)
Globe Newswire (Fri, 13-Nov 6:26 AM ET)
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
Globe Newswire (Tue, 20-Oct 7:30 AM ET)
Zevra Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 7:30 AM ET)
Globe Newswire (Tue, 25-Aug 7:30 AM ET)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 21-Aug 4:30 PM ET)
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Zevra Therapeutics trades on the NASDAQ stock market under the symbol ZVRA.
As of November 17, 2026, ZVRA stock price climbed to $9.40 with 765,861 million shares trading.
ZVRA has a beta of 1.13, meaning it tends to be more sensitive to market movements. ZVRA has a correlation of 0.05 to the broad based SPY ETF.
ZVRA has a market cap of $558.21 million. This is considered a Small Cap stock.
Last quarter Zevra Therapeutics reported $38 million in Revenue and $.18 earnings per share. This beat revenue expectation by $476,688 and exceeded earnings estimates by $.01.
In the last 3 years, ZVRA traded as high as $15.04 and as low as $4.20.
The top ETF exchange traded funds that ZVRA belongs to (by Net Assets): VTI, IWM, JSMD, VXF, XPH.
ZVRA has underperformed the market in the last year with a price return of +5.9% while the SPY ETF gained +10.1%. ZVRA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.0% and -6.9%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
ZVRA support price is $8.86 and resistance is $9.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZVRA shares will trade within this expected range on the day.